Test Description

PROMETHEUS® TPMT Enzyme testing provides a quantitative analysis of a patient’s thiopurine methyltransferase (TPMT) enzyme activity level. Because each patient metabolizes thiopurines differently, the efficacy and toxicity of thiopurines can vary widely from patient to patient. Knowledge of the TPMT enzyme phenotype may reduce time of response, allow physicians to individualize dosing, identify patients in whom thiopurine therapy should be avoided and help reduce the risk of leukopenia.

- A quantitative analysis (phenotype) of TPMT Enzyme activity levels
- **Specimen Requirements** - 5.0 ml Whole Blood in EDTA / Lavender Top Tube
- **Shipping Requirements** – Ambient or cold pack (Do Not Freeze)
- **Storage /Stability** – 24 hours ambient, 8 days refrigerated
- **Turn Around Time** – 3 business days from date of receipt

Test Information

<table>
<thead>
<tr>
<th>Catalog Number</th>
<th>Test Name</th>
<th>Assay</th>
<th>Reference Value</th>
<th>Result Identifier*</th>
</tr>
</thead>
<tbody>
<tr>
<td>3320</td>
<td>TPMT Enzyme</td>
<td>Phenotype</td>
<td>Normal TPMT Activity: &gt;21.0 EU/mL; Intermediate TPMT Activity: 6.0 – 21.0 EU/mL; Low TPMT Activity: &lt;6.0 EU/mL</td>
<td>A00066</td>
</tr>
</tbody>
</table>

*Result identifier provided for use in HL7 applications.

Laboratory Description

- Prometheus is located in San Diego, CA. **Tax ID#** 33-0685754 **NPI#** 1073642641.
- Licensed in several states including New York and California.
- This test was developed and its performance characteristics determined by Prometheus Laboratories Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. Prometheus Laboratories Inc. is a CAP-accredited CLIA laboratory.

CPT Codes (as applied by Prometheus)

- **82657**, TPMT (thiopurine S-methyltransferase) enzyme activity in peripheral RBC
- **82542**, Quantitative HPLC (High Pressure Liquid Chromatography) for 6-methyl-thioguanine

Literature References

- Seidman EG, Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. *Gastroenterol Disord.* 2003;3(suppl 1):S30-S38.

Assays and methods within this test may be covered by one or more US pending or issued patents. For details, please visit [www.prometheuslabs.com](http://www.prometheuslabs.com)

PTM16005 01/16